NCT04489446COMPLETEDPhase 1Phase 2This randomised trial aims to assess the role of sildenafil in improving oxygenation amongst hospitalised patients with COVID19.
Inclusion Criteria: * Adult participant with high clinical suspicion of a SARS-CoV2 infection. * Hypoperfusion of healthy lung areas in a substraction computed tomography angiography within 24 hours of admission to the hospital. Exclusion Criteria: * Requirement of therapy with nitrates of nitrites * Arterial hypotension at presentation * Recent diagnosis of coronary artery disease (\<6 months) * Acute heart failure at presentation * Recent stroke (\< 6 months) * Chronic respiratory failure with CO2 retention * Known hypersensitivity to sildenafil * Advanced liver disease (Child-Pugh class B or higher) * Users of cytochrome P450 3A4 inhibitors (Erythromycin, Ketoconazole, Itraconazole, Saquinavir) * Pulmonary hypertension * Chronic users of phosphodiesterase 5 inhibitors * Requirement of invasive mechanical ventilation at baseline * Decision to limit therapeutic efforts at baseline * Pregnancy or lactation * History of retinitis pigmentosa * Known obstruction to left-ventricular outflow tract * Unwillingness to participate in the trial